Price Crosses Moving Average
|Bid||84.85 x 1300|
|Ask||86.99 x 900|
|Day's Range||84.78 - 85.93|
|52 Week Range||69.10 - 95.19|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||44.67|
|Forward Dividend & Yield||0.98 (1.14%)|
|Ex-Dividend Date||Jun 04, 2020|
|1y Target Est||N/A|
Baxter (BAX) receives FDA approval for Altapore Shape that will provide surgeons versatile options to advance the art of healing and boost clinical outcomes during a surgery.
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
The increases came in a month when many other companies said they would maintain their payouts at current levels or, worse, suspend them.
In this article you are going to find out whether hedge funds think Baxter International Inc. (NYSE:BAX) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]
Baxter (BAX) receives the CE marking and regulatory approval for the Evo IQ Syringe Infusion system that will help in optimizing efficiency for clinicians.
Mexican President Andres Manuel Lopez Obrador on Wednesday ordered an investigation into allegations the former government irregularly awarded lucrative contracts to a firm reportedly owned by the family of his predecessor, Enrique Pena Nieto. "We have to investigate if President Pena Nieto is involved and see how long the company has been operating, what contracts it received ... if they were awarded directly, through tenders," Lopez Obrador said at his daily press conference. Baxter and Plasti-Esteril were not immediately available to comment.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Baxter International Inc. New York, May 20, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Baxter International Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Baxter International Inc. said Tuesday it was raising its quarterly dividend by 11%, to 24.5 cents a share from 22 cents. The health care products company's new dividend will be payable July 1 to shareholders of record on June 5. Based on Monday's stock closing price of $87.27, the new annual dividend rate implies a dividend yield of 1.12%, compared with the yield for the SPDR Health Care Select Sector ETF of 1.62% and the implied yield for the S&P 500 of 2.06%. The stock, which rose 0.8% in premarket trading, has gained 4.4% year to date through Monday, while the health care ETF has lost 4.0% and the S&P 500 has declined 12.0%.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer. On the call this morning, we will be discussing Baxter's first quarter 2020 financial results.
Baxter International is building a base and near a possible buy zone ahead of its next quarterly earnings report, expected on or around Apr. 30.
Baxter International Inc said on Wednesday it would hire up to 2,000 employees globally, including 800 people in the United States, in response to higher demand for its medical devices due to rise in cases of the new coronavirus infections. To address soaring demand for its products, including blood purification systems PrisMax and Prismaflex used to treat acute kidney injury and other conditions, Baxter said it had ramped up production. It also said it was increasing its air freight capacity as well as raising the limit on transportation frequency for critically needed medical devices and medicines between the United States and Europe.
Moody's Investors Service, ("Moody's") assigned a Baa1 rating to Baxter International Inc.'s ("Baxter") senior unsecured notes. For provisional ratings, this announcement provides certain regulatory disclosures in relation to the provisional rating assigned, and in relation to a definitive rating that may be assigned subsequent to the final issuance of the debt, in each case where the transaction structure and terms have not changed prior to the assignment of the definitive rating in a manner that would have affected the rating.